Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease

Coronary Artery Disease

Volumn 22, Issue 7, 2011, Pages 491-496

  Leonard, Deborah A ^a   Merhige, Michael E ^b   Williams, Brent A ^c   Greene, Robert S ^a  

^a NIAGARA UNIVERSITY   (United States)

^b Heart Center of Niagara   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

Author keywords

atherosclerosis; chemokines; coronary artery disease; gene expression; positron emission tomography

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENETIC IDENTIFICATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UP-REGULATION;

EID: 80053655276     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32834b67e2     Document Type: Article

References (37)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874. (Pubitemid 36019640)
3. Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2004; 2:4-9.
4. Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem 2009; 55:239-255.
5. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009; 55:219-228.
6. Vilahur G, Hermandez-Vera R, Molins B, Casani L, Duran X, Padro T, et al. Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J Thromb Haemost 2009; 7:485-493.
7. Sinnaeve PR, Donahue MP, Grass P, Seo D, Vonderscher J, Chibout SD, et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS One 2009; 4:e7037.
8. Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, et al. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics 2011; 4:26.
9. Gould KL. Does coronary flow trump coronary anatomy? JACC Cardiovasc Imaging 2009; 2:1009-1023.
10. Sdringola S, Loghin C, Boccalandro F, Gould KL. Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up. J Nucl Med 2006; 47:59-67. (Pubitemid 46768513)
11. 82Rb on downstream invasive procedure utilization, costs and outcomes in coronary disease management. J Nucl Med 2007; 48:1069-1076. (Pubitemid 47052644)
12. Vondesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:research0034.1-research0034.11.
13. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana Press. 2000; pp. 365-386.
14. Papp AC, Pinsonneault JK, Cooke G, Sadee W. Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. BioTechniques 2003; 34:2-6.
15. Hacking D, Knight JC, Rockett K, Brown H, Frampton J, Kwiatkowski DP, et al. Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun 2004; 5:274-282. (Pubitemid 38961160)
16. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010; 86:192-201.
17. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LD, Tall A. Interleukin 8 is induced by cholesterol loadng of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996; 271:8837-8842. (Pubitemid 26123306)
18. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101:353-363. (Pubitemid 28067332)
19. Lei ZB, Zhang Z, Jing Q, Qin YW, Pei G, Cao BZ, et al. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res 2002; 53:524-532. (Pubitemid 34117704)
20. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 2006; 168:1385-1395.
21. Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2 and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996; 271:20545-20550. (Pubitemid 26281830)
22. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenin RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13:587-596. (Pubitemid 46828480)
23. Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:1460-1467. (Pubitemid 36543360)
24. Mendelsohn MC, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340:18001-1811.
25. Lei ZB, Fu XJ, Lu ZT, Want BC, Liu XL, You NZ. Effect of estradiol on chemokine receptor CXCR2 expression in rats: implications for atherosclerosis. Acta Pharmacol Sin 2003; 24:670-674.
26. Gibbons GH, Liew CC, Goodarzi MO, Rotter JI, Hsueh WA, Siragy HM, et al. Genetic markers: progress and potential for cardiovascular disease. Circulation 2004; 190:IV47-IV58.
27. Anderson JL, Carlquist JF, Horne BD, Hopkins PN. Progress in unraveling the genetics of coronary artery disease and myocardial infarction. Curr Atheroscler Rep 2007; 9:179-186. (Pubitemid 47629065)
28. Tuncman G, Erbay E, Hom X, DeVivo I, Campos H, Rimm EB, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103:6970-6975.
29. Pearce E, Tregouet DA, Samnegard A, Morgan AR, Cox C, Hamsten A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 2005; 97:958-960.
30. Bennermo M, Held C, Green F, Strandberg LE, Ericsson CG, Hansson LO, et al. Prognostic value of plasma interleukin-6 concentrations and the-174 G > C and-572G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004; 174:157-163. (Pubitemid 38595452)
31. 0flanking region: relations between the sequence variants, fasting plasma total ghrelin concentrations, and body mass index. Metabolism 2006; 55:1420-1425. (Pubitemid 44353562)
32. Sprenger H, Lloyd AR, Kelvin DJ. Promoter analysis of the human interleukin-8 receptor genes, IL-8RA and IL-8RB. Immunobiology 1995; 193:334-340.
33. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 2006; 18: 1101-1113. (Pubitemid 43923428)
34. Racchi M, Sinforiani E, Govoni S, Marinovich M, Galli CL, Corsini E. RACK-1 expression and cytokine production in leukocytes obtained from AD patients. Aging Clin Exp Res 2006; 18:153-157. (Pubitemid 43833635)
35. Nishida M, Nasu K, Fukuda J, Kawano Y, Narahara H, Miyakawa I. Down-regulation of interleukin-1 receptor type 1 expression causes the dysregulated expression of CXC chemokines in endometriotic stromal cells: a possible mechanism for the altered immunological functions in endometriosis. J Clin Endocrinol Metab 2004; 89:5094-5100. (Pubitemid 39391454)
36. Shen H, Lentsch AB. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 2004; 286:C840-C847. (Pubitemid 38543813)
37. Robbesyn F, Salvayre R, Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res 2004; 38:541-551. (Pubitemid 38697088)